The CLL Sessions: highlights from EHA and ICML 2021
VJHemOnc Podcast
00:00
Comparing the Efficacy and Side Effects of Akylobrutinib and Britinib in CLL Patients
This chapter discusses two different studies comparing the efficacy and adverse events of a second-generation VTK inhibitor, akylobrutinib, with a britinib in high-risk patients with CLL. The first study focuses on the non-inferiority of akylobrutinib compared to a britinib in terms of progression-free survival, while the second study examines the occurrence of atrial fibrillation and other adverse events. The analysis suggests that akylobrutinib has a lower rate of cardiovascular adverse events, particularly atrial fibrillation, compared to a britinib.
Transcript
Play full episode
